Odefsey generic
Odefsey is an anti-HIV drug owned by Gilead Sciences Inc. Its active ingredients include Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Fumarate. Odefsey was first authorized for market use on 01 March, 2016 and it holds a total of 10 drug patents, 3 of which have already expired.
When will Odefsey generic be available?
The generic versions of Odefsey are due to be released after 15 February, 2033. The patent US8754065*PED titled 'Tenofovir alafenamide hemifumarate' which expires on 2033-02-15 appears to be the one holding back the release of a generic version.
Odefsey uses
Odefsey is primarily used for the treatment of HIV infection. The effectiveness of Odefsey comes from its active ingredients: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Fumarate which work together to stop the virus from multiplying in the body thus helping control the infection.
Odefsey patent expiration
Odefsey has 10 patents, the last of which is expected to expire on February 15, 2033. This expiry date will most likely dictate the earliest possible release of an Odefsey generic. Below are the details of the patents: